Jeff Jones

Stock Analyst at Oppenheimer

(0)
# 4906
Out of 5,358 analysts
110
Total ratings
20.73%
Success rate
-24.47%
Average return
27 Stocks
Name Action PT Current % Upside Ratings Updated
YMAB Y-mAbs Therapeutics
Maintains: Outperform
20 15
5.25 185.71% 3 May 29, 2025
CMMB Chemomab Therapeutic...
Maintains: Outperform
11 10
1.34 646.27% 8 May 16, 2025
ALMS Alumis
Maintains: Outperform
26 25
3.58 598.32% 2 May 15, 2025
ZURA Zura Bio
Maintains: Outperform
19 17
1.26 1249.21% 4 May 9, 2025
CRVS Corvus Pharma
Reiterates: Outperform
15 17
3.92 333.67% 5 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
85 86
37.26 130.81% 2 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
60 56
9.24 506.06% 9 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
28 18
8.32 116.35% 4 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 5 Dec 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
22 16
3.33 380.48% 7 Nov 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
10 9
2.45 267.35% 10 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
52 56
47.64 17.55% 4 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
35 39
23.6 65.25% 2 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
48 45
1.62 2677.78% 6 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 4 Jun 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Perform
n/a
n/a n/a 3 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
32 30
n/a n/a 3 Feb 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 15
n/a n/a 3 Jan 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 3 Jun 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
1920
0.36 533233.33% 3 May 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
n/a n/a 2 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
15
0.97 1446.39% 5 May 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
75
0.67 11094.03% 2 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
125 150
n/a n/a 6 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
1600 1100
3.11 35269.77% 2 Nov 17, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
193
n/a n/a 1 Jul 18, 2022